Results: To address the above issues, we proposed a novel approach to disentangling and eliminating 9 irrelevant factors by leveraging the power of deep learning. Specifically, we designed a deep learning 10 framework, referred to as DeepType, that performs joint supervised classification, unsupervised clus-11 tering and dimensionality reduction to learn cancer-relevant data representation with cluster structure.
Introduction

22
Human cancer is a heterogeneous disease initiated by random somatic mutations and driven by multiple 23 genomic alterations (Hanahan and Weinberg, 2011; Sun et al., 2017) . In order to move towards personal- 
29
Most early work on molecular subtyping has been performed on data obtained from breast cancer 30 tissues (Sørlie et al., 2001 (Sørlie et al., , 2003 . Typically, breast cancer is not lethal immediately, and thus there 31 is an opportunity to assist with prognostication and patient management using molecular information.
32
Molecular subtyping of breast cancer initially focused on mRNA data obtained from microarray platforms 33 and parsed molecular profiles to stratify patients according to clinical outcomes (Sørlie et al., 2001) .
34
Refinement of the subtype categories through validation in independent datasets identified five broad The desire for levels of accuracy that can ultimately lead to clinical utility continues to drive the learning based approaches may not enable us to identify novel subtypes. This is because the primary goal 54 of supervised learning is to identify genes to achieve the maximum separation of samples from different 55 subtypes, and genes that support novel subtypes can be considered irrelevant and removed. Consequently, 56 most existing methods were developed within the unsupervised-learning framework. Representative work 57 includes SparseK (Witten and Tibshirani, 2010) , iCluster (Shen et al., 2009 (Shen et al., , 2013 ) and non-negative 58 matrix factorization (Kormaksson et al., 2012) . A major issue with existing methods is that there is 59 no guarantee that subtypes identified through de novo clustering are biologically relevant. Presumably,
60
genomics data records all ongoing biological processes in a cell or tissue, where multiple factors interact 61 with each other in a complex and entangled manner. Tumor samples can be grouped based on factors that 62 are not related to the actual disease (e.g., race and eye color). A possible way to address the issue is to 63 use previously established results to guide the detection of new subtypes. However, as the name suggests, 64 de novo clustering completely ignores results from previous efforts. Another major limitation is that Figure 1 : Overview of the proposed deep learning based method for cancer molecular subtyping. It consists of three major components: representation learning, prior knowledge integration, and subtyping. The first part maps raw genomics data onto a representation space, the second part incorporates prior biological knowledge to guide representation learning, and the third part generates subtyping results. The network parameters are learned by minimizing a unified objective function consisting of a classification loss, a clustering loss and a sparsity penalty. perform preprocessing and retain only the most variant genes (Curtis et al., 2012) . However, there is no 72 guarantee that low-variant genes contain no information and the cut-offs used to select variant genes were 73 usually set somehow arbitrarily.
74
The above observations motivated us to develop a novel deep-learning based approach, referred to as easily performed by using a mini-batch gradient descent method. Thus, our method can handle large 84 datasets with extremely high dimensionality. Although the idea of using deep learning for clustering is 85 not new (see, e.g., Xie et al. (2016) ), to the best of our knowledge, this work represents the first attempt to 86 use deep learning to perform joint supervised and unsupervised learning for cancer subtype classification.
87
A large-scale experiment was performed that demonstrated that DeepType significantly outperformed the 88 existing approaches. The new approach provides a framework for the derivation of more accurate and 89 robust molecular cancer subtypes by using increasingly complex genomic data. 
91
In this section, we present a detailed description of the proposed method for cancer subtype identification.
92
We also propose novel procedures for optimizing the associated objective function and estimating the 93 hyper-parameters. samples (e.g., subtyping results from previous studies), where x n ∈ R D is the n-th sample and y n ∈ R J is 97 the corresponding class label vector with y jn = 1 if x n belongs to the j-th group and 0 otherwise. Our goal 98 is to identify a small set of cancer related genes and perform clustering analysis on the detected genes to 99 refine existing classification systems and detect novel subtypes. To this end, we utilize the representation 100 power of a multi-layer neural network to project raw data onto a representation space where clusters 101 can be easily detected. As discussed above, clusters identified through unsupervised learning may not be 102 biologically relevant. To address the issue, we impose an additional constraint that the detected clusters 103 are concordance with previous results. Specifically, we cast it as a supervised-learning problem, that is,
104
to find a representation space where the class labels can be accurately predicted.
105
Figure 1 depicts the network structure of the proposed method. It consists of an input layer, M 106 hidden layers, a classification layer and a clustering module. The M -th hidden layer is designated as the 107 representation layer, the output of which is fed into the classification layer and the clustering module.
108
Mathematically, the neural network can be described as follows:
where W m , b m , and o m are the weight matrix, bias term and output of the m-th layer, respectively, and 
115
We optimize network parameters Θ through joint supervised and unsupervised learning by minimizing 116 an objective function that consists of a classification loss, a clustering loss and a regularization term. The 117 classification loss measures the discrepancy between the predicted and given class labels. By construction,
118
the j-th element ofȳ n can be interpreted as the probability of x n belonging to the j-th group. Thus, we 119 use the cross entropy to quantify the classification loss:
We use the K-means method (Lloyd, 1982) to detect clusters in the representation space. The loss 121 function optimized by K-means is given by
subject to K k=1 s kn = 1, s kn ∈ {0, 1}, ∀k, ∀n, where K is the number of clusters, C is a center matrix
123
with each column representing a cluster center, and s n is a binary vector where s kn = 1 if x n is assigned 124 4 to cluster k and 0 otherwise. Finally, we impose an 2,1 -norm regularization (Nie et al., 2010) on the 125 weight matrix of the first layer to control the model complexity and to select cancer related genes:
where W 1ij is the ij-th element of W 1 and D 2 is the number of the nodes in the second layer. The 127 2,1 -norm regularization has an effect of automatically determining the number of nodes activated in the 128 input layer, and thus the number of genes used in downstream subtyping analysis.
129
Combining the above three losses, we obtain the following novel formulation for cancer subtype iden-
where 
where α is a tradeoff parameter that controls the balance between the classification and clustering perfor- 
Optimization
140
The above optimization problem contains three sets of variables, namely, network parameters Θ, assign-141 ment matrix S, and cluster centers C. It is difficult to solve the problem directly since the parameters 142 are coupled and S is a binary matrix. To address the issue, we partition the variables into two groups, i.e., Θ and (S, C), and employ an alternating optimization strategy to solve the problem. Specifically, we 144 first perform pre-training to initialize the network by ignoring the clustering module (i.e., setting α = 0).
145
Then, we fix Θ and transform the problem into
which can be readily solved by using the standard K-means method. Then, we fix (S, C) and write the 147 problem as
which can be optimized through back-propagation by using the mini-batch based stochastic gradient error that is within one standard deviation of the one obtained by setting α = 0 (i.e., we require that the 167 obtained classifier does not perform significantly worse than the existing subtyping system), and record 168 the corresponding average silhouette width s i . Once we run over all possible K i , we obtain T + 1 triplets
. Finally, we determine the number of clusters K and the tradeoff parameter α as the pair 170 that yields the largest average silhouette width. The pseudo-code of the proposed procedure is given in
171
Algorithm S1, and the proposed procedure performed quite well in our numerical experiment (see Figure   172 S1).
173
Experiments
174
We conducted a large-scale experiment on breast and bladder cancers to demonstrate the effectiveness of 175 the proposed method. Due to space limit, here we report only the results of the breast cancer study and 176 present the bladder cancer results in Supplementary Data. layer, the two hidden layers and the output layer were set to 20,000, 1,024, 512, and 6, respectively. We rate was set to 1e-3, the numbers of training epochs for model initialization and the joint supervised and 189 unsupervised training were set to 300 and 1,500, respectively, and the batch size was set to 256. By 190 using the method proposed in Section 2.3, the number of clusters K, the tradeoff parameter α and the 191 regularization parameter λ were estimated to be 11, 1.2 and 0.006, respectively (see Figure S1 ). To ensure 192 that the constructed model did not overfit the data, we tracked the training and validation losses in the 193 training process (see Figure S2 ), and no sign of over-fitting was observed. 
Clinically Relevant Subtypes Revealed by DeepType
195
By applying the proposed method to the breast cancer dataset, a total of 218 genes were selected and 11
196
clusters were detected. To visualize the identified clusters, we applied t-SNE (van der Maaten and Hinton, the ten subtypes were associated with distinct prognostic outcomes (logrank test, p-value < 1.22e-19). Figure 3: Visualization of the sample distributions of the clusters detected by three methods applied to data containing 10,000 most variant genes. Each sample was color-coded by its clustering assignment (top) and PAM50 label (bottom). DeepType revealed a clear eleven-cluster structure including a cluster comprising primarily normal tissue samples.
3.4. 
Comparison Study
224
To further demonstrate the effectiveness of the proposed method, we compared it with two state-of-the- 
239
We first visualized the sample distributions of the clusters detected by the three methods ( Figure   240 3). Since iCluster failed on the datasets with 15,000 and 20,000 genes due to the need of performing 241 matrix inversion of high-dimensional data, we considered only the results generated by using the dataset 242 with 10,000 genes. We can see that DeepType identified eleven well-defined clusters, nearly all normal 243 tissue samples were grouped into a single cluster, and the clusters that composed of tumor samples were 244 well-separated and highly concordant with the PAM50 labels. In contrast, for SparseK and iCluster, the 245 normal tissue samples were grouped into multiple clusters, which suggests that genes unrelated to cancer 246 were selected. Moreover, the tumor samples with different PAM50 labels overlapped considerably, and 247 did not exhibit a clear clustering structure.
248
We then performed a series of external and internal evaluations of the clusters detected by the three vs. iCluster).
266
We next performed internal evaluation of the subtypes identified by the three methods. Internal Davies-Bouldin index (Davies and Bouldin, 1979) to quantify the cluster compactness and separability.
273
The results are reported in Table 2 . In all cases, DeepType resulted in the highest silhouette width and 274 the lowest Davies-Bouldin index, which is consistent with the visualization result presented in Figure 3 .
275
To compare the overall performance, the Wilcoxon rank-sum test was performed. Deeptype significantly
276
outperformed SparseK (p-value ≤ 7.8e-5) and iCluster (p-value ≤ 7.8e-5). Our analysis suggested that 277 our method resulted in subtypes with significantly higher cluster quality than the competing methods.
278
Finally, we compared the ability of the three methods to select relevant genes from high-dimensional 279 data for clustering analysis. Table 3 reports the numbers of genes selected by the three methods applied to 
Validation Study
285
To demonstrate the generalization capability of the proposed method, we performed a validation study of cancer subtypes and we have showed that our approach performed well in the presence of label noise.
328
Further investigations are warranted to explore such possibilities.
329
In this paper, we presented a proof-of-concept study considering only gene expression data. Several design a network to process multiple data types (Wang et al., 2015) . As the future work, we will perform 335 a large-scale experiment to look into this issue to identify the optimal network structure for genomics 336 data analysis. It is expected that more accurate and robust cancer subtypes would be revealed. 
; 2 Estimate λ * through ten-fold cross validation; 3 Compute average classification error e 0 and one standard error σ 0 ; 4 EstimateK by maximizing average silhouette width;
Solve Problem (6); end
where K is the number of clusters, C is a center matrix with each column representing a cluster center, and s n is a binary vector where s kn = 1 if x n is assigned to cluster k and 0 otherwise.
Finally, we impose an`2 ,1 -norm regularization on the weight matrix of the first layer to control the model complexity and to select cancer related genes:
where W 1ij is the ij-th element of W 1 and D 2 is the number of the nodes in the second layer. It has an effect of automatically determining the number of nodes used in the input layer, thus the number of genes used in cancer subtyping analysis. Combining the above three losses, we obtain the following formulation for cancer subtype identification:
where S = [s 1 , · · · , s N ] is an assignment matrix, is a regularization parameter that controls the sparseness of a solution, and ↵ controls the tradeoff between the classification and clustering performance. In the following sections, we describe how to solve the above optimization problem and estimate the hyper-parameters.
Optimization
The above optimization problem contains three sets of variables, i.e., network parameters ⇥, assignment matrix S, and cluster centers C. It is difficult to solve the problem directly since the parameters are coupled and S is a binary matrix. To address the issue, we divided the variables into 
S1 Bladder Cancer Study
S1.1 Experiment Setting
The bladder cancer dataset was obtained from the TCGA project, which contains the expression profiles of 20,241 genes from 427 bladder tumor samples. We classified each tumor sample into one of the two UNC subtypes (Damrauer et al., 2014) , namely luminal and basal, using the R package BLCAsubtyping (Kamoun et al., 2019) , and used the UNC subtypes as the class labels. For model construction and performance evaluation, we randomly partitioned the data into a training and test dataset, containing 80% and 20% of the samples, respectively. Since the sample size is small, in order to avoid possible overfitting, we used only the top 10,000 most variant genes, and designed a three-layer neural network with 10,000, 32 and 2 nodes in the input layer, the hidden layer and the output layer, respectively. The number of clusters K, the tradeoff parameter α and the regularization parameter λ were estimated to be 4, 0.005 and 0.002, respectively. Other experiment settings were similar to those used in the breast cancer study.
S1.2 Clinically Relevant Subtypes Revealed by DeepType
By applying DeepType to the bladder cancer dataset, a total of 156 genes were selected and 4 clusters were detected. The descriptions of the selected genes are given in Table S5 . To visualize the detected clusters, we applied t-SNE (van der Maaten and Hinton, 2008) to the outputs of the representation layer. Figure S4 (a-b) presents the sample distributions of the identified clusters and their UNC-subtype compositions, respectively. We can see that the tumor samples were grouped into four well-defined clusters, including two luminal dominated clusters (labeled as luminal 1 and 2) and two basal dominated clusters (labeled as basal 1 and 2). To demonstrate the clinical relevance of the identified tumor subtypes, a survival data analysis was performed. Figure S4 (c) shows that the four subtypes are associated with distinct prognostic outcomes (logrank test, p-value < 0.0001).
Further internal and external validation analysis is presented in Section S1.3. Figure S4 (d) presents the heatmap of the 156 selected genes. We can clearly see two modules, one containing key genes MSN, TNC and MUC16, and the other containing key genes TOX3 and PDX1. The difference in the gene expressions in the two modules divided the samples into two broad categories, i.e., basal and luminal. Specifically, the basal samples have high expressions in the MSN module and low expressions in the TOX3 module, and the luminal samples are on the contrary. Within each UNC subtype, luminal 1 has higher expressions in the MSN module than luminal 2, while basal 1 has higher expressions in the TOX3 module than basal 2. Using t-test and the Benjamini-Hochberg procedure (Benjamini and Hochberg, 1995), we identified 99 genes differentially expressed between luminal 1 and luminal 2, and 112 genes between basal 1 and basal 2 (FDR ≤ 0.05). Our analysis showed that DeepType is able to identify novel bladder cancer subtypes beyond the UNC subtyping system that are associated with distinct expression patterns.
S1.3 Comparison Study
For comparison, we applied SparseK and iCluster to the bladder cancer dataset. The parameters of the two methods were estimated in the same way as that used in the breast cancer study. We first visualized the sample distributions of the clusters detected by the three methods ( Figure S5 ). As with the breast cancer study, we can see that the clusters identified by DeepType are much more compact than those detected by SparseK and iCluster. Then, we performed a series of external and internal evaluations of the quality of the identified clusters. For external evaluation, we assessed the concordance between cluster assignments and the UNC subtypes, the tumor pathological stages, and the risk of tumor recurrence computed based on a three-gene signature proposed in (Liu et al., 2017) (see Table S6 for a detailed description). For internal evaluation, we used the silhouette width and Davies-Bouldin index to quantify the compactness and separateness of the obtained clusters. The results are reported in Tables S7 and S8 . In terms of external criteria, our method performed significantly better than SparseK and slightly better than iCluster. In terms of internal criteria, DeepType resulted in the highest silhouette width and the lowest Davies-Bouldin index, which is consistent with the visualization result presented in Figure S5 . Our analysis suggested that our method resulted in subtypes with significantly higher cluster quality than the competing methods. 
SparseK
Basal Luminal Figure S5 : Visualization of the sample distributions of the clusters detected by three methods applied to the bladder cancer dataset. Each sample is color-coded by its clustering assignment (top) and UNC-subtype label (bottom). DeepType revealed a clear four-cluster structure. 
